Single-Cell Chemistry of Photoactivatable Platinum Anticancer Complexes

The Pt(IV) prodrug trans, trans, trans-[Pt(pyridine)(2)(N-3)(2)(OH)(2)] (Pt1) and its coumarin derivative trans, trans, trans-[Pt(pyridine)(2)(N-3)(2)(OH)(coumarin-3-carboxylate)] (Pt2) are promising agents for photoactivated chemotherapy. These complexes are inert in the dark but release Pt(II) species and radicals upon visible light irradiation, resulting in photocytotoxicity toward cancer cells. Here, we have used synchrotron techniques to investigate the in-cell behavior of these prodrugs and visualize, for the first time, changes in cellular morphology and Pt localization upon treatment with and without light irradiation. We show that photoactivation of Pt2 induces remarkable cellular damage with extreme alterations to multiple cellular components, including formation of vacuoles, while also significantly increasing the cellular accumulation of Pt species compared to dark conditions. X-ray absorption near-edge structure ( XANES) measurements in cells treated with Pt2 indicate only partial reduction of the prodrug upon irradiation, highlighting that phototoxicity in cancer cells may involve not only Pt(II) photoproducts but also photoexcited Pt(IV) species.

Automated summary

The Pt(IV) prodrug Pt2 shows remarkable photocytotoxicity towards cancer cells, inducing significant cellular damage and vacuole formation, along with increased accumulation of Pt species in cells compared to dark conditions. Synchrotron techniques reveal only partial reduction of Pt2 upon irradiation, suggesting that phototoxicity in cancer cells may involve both Pt(II) photoproducts and photoexcited Pt(IV) species.